Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

Apps as medical devices – UK regulator updates its guidance

MHRA moves to help firms' health apps comply with its rules

- PMLiVE

Takeda: No decision yet on shutdown of Cambridge, UK unit

Tells PMLiVE that consultation over proposed closure of R&D site still ongoing

- PMLiVE

Joe Tardibuono joins HealthSTAR Communications

Brings experience from FCB Health and Forest Laboratories

- PMLiVE

Life appoints Sophie Gibbs

She joins the UK creative comms agency as a senior account manager

Novartis day

Novartis drug works in secondary progressive MS

Orally-active siponimod reduces risk of disability progression

A stumble, but not a fall – what’s next for Opdivo?

Blue Latitude Health's Louis Perdios talks about the daunting challenges faced by BMS after Opdivo's disappointing results.

Blue Latitude Health

- PMLiVE

FDA knocks back Amgen’s chronic kidney disease treatment

Parsabiv was hoped to equal or exceed solid earner Sensipar

- PMLiVE

Surging sales of Lundbeck’s CNS drugs assist recovery

Two newer antidepressants help boost sales after Cipralex patent ends

AstraZeneca AZ global R&D corporate HQ

AZ slims down again with sale of antibiotics to Pfizer

Deal does not include biologic anti-infective products from Medimmune unit

- PMLiVE

AbbVie’s venetoclax set for early access in UK

Drug for CLL patients included in EAMS by MHRA

- PMLiVE

NICE backs Xalkori for lung cancer, but may cut two others from CDF

Preliminary verdict could lead to removal of Novartis' Afinitor and Janssen's Imbruvica from the Fund

Gilead Sciences

Gilead’s Truvada cleared for HIV prevention in EU

May help slow down recent uptick in new HIV diagnoses

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links